共 321 条
- [1] Shahinian VB(2006)Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist J Natl Cancer Inst 98 839-845
- [2] Kuo YF(2011)Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States Urol Oncol 29 647-653
- [3] Freeman JL(2014)American Cancer Society prostate cancer survivorship care guidelines CA Cancer J Clin 64 225-249
- [4] Goodwin JS(2010)Reimbursement policy and androgen-deprivation therapy for prostate cancer N Engl J Med 363 1822-1832
- [5] Gilbert SM(2015)Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate Cancer Eur Urol 68 805-811
- [6] Kuo YF(2014)Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer J Clin Oncol 32 1324-4840
- [7] Shahinian VB(2017)Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer Cancer 123 4832-2131
- [8] Skolarus TA(2007)Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2106-479
- [9] Wolf AM(2014)EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 467-137
- [10] Erb NL(2014)EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013 Eur Urol 65 124-39